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Abstract
Necrotizing enterocolitis (NEC) is a typical disorder of preterm newborns, with a high mortality and morbidity rate.
The therapeutic and nutritional management of disease depends on several factors. Its prognosis is linked, in
addition to the severity of the disease and the need for surgery, to a correct enteral feeding in these patients. This
study aims to identify the clinical characteristics of 18 patients with NEC, evaluating the different therapeutic paths
undertaken, the type of formula used and the survival rate of this population. Average time of enteral nutrition
before the NEC onset was 11,3 ± 11,6 days, with an average fasting period since the onset of 24 ± 18.9 days. 77.8%
of patients received surgery and resumed enteral nutrition 17.7 ± 17.9 days after the intervention. The overall
survival rate of our cohort was 55.5%. More prospective studies are needed to evaluate the long-term outcomes of
survived children with NEC.
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Introduction
Necrotizing enterocolitis (NEC) is a critical disease
typical of premature infants. Although its incidence
varies among different neonatal intensive care units, the
average prevalence among very low birth weight infants
(VLBW), defined as those with a first recorded weight <
1500 g, is 7% [1, 2]. The intestinal barrier immaturity
and a gut microbiota dysbiosis could probably contribute
to the intestinal inflammation and the damage observed
in these patients [1, 3].
The Bell’s staging, introduced in 1978 and later modi-
fied by Kligeman and Walsh, stratifies the severity of this
pathology and guide the treatment approach [4]. In Bell’s
stages I and II, corresponding to cases of just suspected
or mild to moderate NEC, therapy consists of a broad-
spectrum antibiotic therapy and parenteral nutrition,
with a contemporary suspension of enteral nutrition for
an average of 7 to14 days. In cases of worsening of
symptoms or severe disease (stage III), hemodynamic in-
stability, low platelets, CID, peritonitis or pneumoperito-
neum are frequent findings. In these cases, surgery is
generally indispensable [5]. Mortality rate found among
NEC cases which needed surgery rises from 3 to 30%
[6]. Furthermore, when a massive intestinal resection is
performed, short bowel syndrome can result [5]. On a
histological level, indeed, after massive resections, adap-
tations of the remaining bowel structure have been ob-
served, like a lengthening of villi, a deepening of crypts
and an increase in the proliferation of enterocytes. These
changes increase the absorption capacity of the residual
bowel [7].
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The purpose of this study is to evaluate a population
of patients affected by NEC, collecting their clinical data
and analyzing the nutritional implications of disease.
Material and methods
An observational prospective study was carried out
through the collection of cases of NEC admitted to the
Neonatology and Neonatal Intensive Care Unit of
“Policlinico P. Giaccone”, Palermo between January 2015
and January 2019. We revised the medical records of
these infants; data were extrapolated with a standardized
table. The main outcome of this study was to evaluate
the survival rate, distribution and characteristics of NEC
patients in a single cohort, evaluating different ap-
proaches utilized and observing their possible clinical
outcomes.
Clinical data that have been collected were clinical
condition and age at diagnosis, progression of disease,
therapeutic nutritional and surgical management. For
each patient a multidisciplinary evaluation has been
carried out through joint visits, with the presence of
pediatrician, surgeon, parents. Categorical variables were
synthesized with frequencies, percentages and statistical
distribution.
The study was conducted according to the guidelines
of the Declaration of Helsinki, and it has been approved
by the ethical committee of the center involved.
Results
In total, 18 infants were included in the study: 8 males
and 10 females (Table 1). The gestational age (GE) at
birth was between 23 + 6 week and 35 + 2 week, with an
average of 29 + 1. 13 infants had GE < 32 w, 3 had GE
between 32 and 33 w and 6 days, 2 were late preterm
(GE between 34 and 36 w and 6 days). The smaller in-
fant weighed 600 g, while the bigger one weighed 2130 g.
The average weight found at birth was 1078 ± 478,96 g. 4
infants were low birth weight (LBW) (< 2500 g), 4 were
very low birth weight (VLBW) (< 1500 g), 10 were ex-
tremely low birth weight (ELBW) (< 1000 g). All the in-
fants in our population were preterm, some had specific
comorbidities; in 2 genetic pathologies were found, in 5
a patent ductus arteriosus was found. In 1 newborn a
hypertrophic heart disease was diagnosed. 3 newborns
were from bigeminal pregnancies, 15 from single ones.
Regarding severity of NEC, 14 infants were on stage III
of Bell, 4 on stage II and no one was on stage I. 8 new-
borns died during the hospitalization, of which 7 were
on stage III and 1 on stage II. The survival rate of our
population was 55.5%. Figures 1 and 2 describe the dis-
tribution of cases for gestational age and weight at birth.
Enteral nutrition
In our case series, enteral nutrition started on average
after 6.7 ± 9.6 days of life. This delay in starting nutrition
could be related to prematurity. Considering the type of
milk administered before NEC, 5 groups of newborns
were identified: 2 newborns were fed with breast milk
and hydrolyzed formula, 5 with breast milk and preterm
formula, 2 with preterm formula and 8 with breast milk
only; 1 newborn developed NEC before the initiation of
enteral feeding. In the 17 newborns who developed NEC
after the beginning of enteral feeding, it was stopped for
food intolerance after 15.5 ± 13 days of life. Infants of
this case series performed enteral nutrition for 11,3 ±
11,6 days before the NEC onset. Considering the interval
between disease onset and enteral reintroduction, an
average fasting period of 24 ± 18.9 days was performed.
Figure 3 describes the days distribution for the enteral
fasting after NEC onset.
The time to reach a full enteral feeding was evaluated
by measuring the interval between the day of enteral re-
introduction and the day of parenteral stop. 8 infants
were excluded (7 for an early exitus and 1 for lack of
clinical data).
Table 2 sums up types of milk administered during
the enteral feeding reintroduction phase.
Parenteral nutrition
In our series, due to the prematurity, many infants
started parenteral nutrition before NEC onset. It should
be noted that in the event of death, the day of exitus was
considered the day of parenteral suspension. On average,
infants in our population practiced parenteral nutrition
for 50 ± 28 days. Regarding the composition of the par-
enteral formula administered,12 newborns received olive
oil lipid emulsions, 5 received soy-bean lipid emulsions
and 1 received parenteral with lipid-free formula.
Surgery
4 patients did not have surgery (22.2%) and 14 had sur-
gery (77.8%). Surgery was performed on average after
32.5 ± 27.1 days of life. Among operated infants, 5 had
an intestinal resection with ileostomy placement (27.8%),
4 had only ileostomy packaging (22.2%), 1 had a colos-
tomy, 2 had neither resection nor ileostomy. 2 patients
were treated exclusively with an abdominal drainage.
Within the group of operated infants, the reintroduction
Table 1 Baseline patients’ characteristics
Newborns 18
Sex ratio M/F 0,8
Gestational age (Week) 29 + 1 [I.C. 23+ 6–35+ 2]
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of enteral nutrition occurred on average after 17.7 ±
17.9 days from surgery.
Use of supplements and medications
Iron, D and K vitamins supplementation is essential in
preterm newborns [8] Our population, in addition to the
inherent risk of prematurity, was more exposed to a vita-
min malabsorption and to trace elements lack. In addition
to this, newborns who practice parenteral nutrition for
long periods may develop carnitine deficiency [8]. We
evaluated vitamin supplementation in our population: 2
newborns received carnitine, 4 oral iron, 1 injected trace
elements and 9 received oral multivitamins.
We evaluated the administration of antacids and urso-
deoxycholic acid (UDCA) in our population, trying to
identify an indirect parameter that would give us an
overview on main gastroenterological sequences of NEC
(ex. gastric hypersecretion and liver disease). Many neo-
nates with NEC, especially those who had jejunostomies,
showed an increased gastric secretion that may require
antacids [5]. In our population 6 infants received antia-
cids. Furthermore, infants with NEC, due to a prolonged
parenteral nutrition, show higher risk of developing liver
disease and cholestasis. These conditions need for nutri-
tional modifications and UDCA supplementation. In our
population 4 infants received UDCA.
Fig. 1 Patients for gestational age at birth (weeks) distribution
Fig. 2 Born weight distribution (g)
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Signs and symptoms of NEC
Many clinical and radiological signs were evaluated from
the onset of NEC. Principal signs of food intolerance
which brought to the interruption of enteral feeding
were abdominal distension (83.2%), stagnation (33.3%)
and intestinal bleeding (27.7%) (Table 3). Most frequent
systemic signs were the increase of inflammation indices
(55.5%) and thrombocytopenia (27.8%) (Table 4). Radio-
logical findings observed were pneumoperitoneum
(38.9%), hydro-aerial levels (38.9%) and failure to gasify
the rectum (33.3%) (Table 5). Portal pneumatosis and
aerobilia were less frequent radiological signs.
Discussion
Main problems in the prevention of NEC concern the
introduction of enteral nutrition and the type of admin-
istered formula. 10 newborns started enteral feeding in
the first 2 days of life, but on average enteral nutrition
was started 6.7 days after birth. This variability could be
referred to the heterogeneity of gestational ages. Recent
evidences state that early enteral nutrition, despite not
being a protective factor, does not increase the incidence
of NEC, but allows a faster growth and reduces the risk
of sepsis and food intolerance [9, 10]. Concerning the type
of formula introduced, breast milk has been shown as a
protective factor [11]. The incidence of NEC in breast-
only infants is indeed 6–10 times lower than an adapted
formula exclusive feeding [12]. Several non-nutritious
components of breast milk contribute to the immune
function of the gastrointestinal tract and increase the in-
tegrity of the mucous membrane [9, 10]. Some of these
components are IgA, growth factors and polyunsaturated
fatty acids. The beneficial effects of human milk are also
linked to the presence of oligosaccharides capable of
stimulating the growth of a healthy bacterial flora [13–17].
In our case series, the absence of infants with stage I
NEC may be linked to a failure of early diagnosis, due to
the birth in other hospitals. The development of specific
biomarkers could help in the differential diagnosis. The
high prevalence of NEC at stage III of our case studies
(78%) it is probably linked to the presence of a Pediatric
Surgery Ward in the same departmental complex. Low
birth weight and high prevalence of surgical NECs could
explain the total high mortality rate in our sample
(44.5%), which is higher than the mortality described in
other reports [5].
Fig. 3 Distribution enteral fasting days after NEC onset
Table 2 Type of enteral nutrition reintroduced during the
healing phase
Type of formula Newborns
Hydrolyzed formula 4
Breast milk only 5
Breast milk and hydrolyzed formula 3
Breast milk and preterm formula (0) 2
Not refed due to early death 4
Table 3 Intestinal signs of NEC
n %
Distended abdomen 15 83.2
Biliary gastric stagnations 7 38.9
Hematochezia 4 22.2
Melena 1 5.6
Closed alvo 1 5, 6
Rectorrhagia 1 5.6
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NEC medical treatment
Medical NEC therapy consists of the administration of
broad-spectrum antibiotics, the fasting and the initiation
of parenteral nutrition. The duration of fasting depends
on clinical, laboratory and instrumental evaluation [18].
According to recent evidence, early reintroduction of en-
teral feeding is associated with fewer complications,
shorter duration of antibiotic therapy, faster progression
to nutritional goals by age, and shorter hospitalization
[19, 20]. A recent review [5] suggests that in patients on
stage 1 and 2, fasting must last between 7 and 14 days.
Conversely, a meta-analysis reports that there are no
significant differences in terms of complications if the
enteral is introduced before the fifth day [19]. A pro-
longed enteral fasting could have multiple negative
consequences:
 favors the development of deficiencies in vitamins
and nutrients
 determines atrophy of the intestinal mucosa
 promotes bacterial overgrowth
 prolonged parenteral nutrition increasing its
infectious and metabolic complications.
Clinicians should minimize fasting, reintroducing en-
teral nutrition as soon as there is a clinical improvement
witnessed by the stability of vital signs, the abdominal
physical examination, and the normalization of platelet
count and radiologic signs The identification of bio-
markers (NIRS, I-FABP, intestinal alkaline phosphatase)
[21, 22], capable of reflecting the severity of NEC and in-
testinal recovery, could help to personalize the moment
of resumption of enteral feeding, minimizing the conse-
quences of a prolonged fasting. In addition to the correct
timing for the resumption of enteral nutrition, the type
of formula to be used is an important factor. The super-
iority of breast milk seems undisputed, but when it is
not available, it is not known whether the adapted for-
mula or the hydrolysate is preferable. In our series, 10
newborns resumed enteral nutrition with breast milk (5
exclusively, 3 associated with hydrolyzed formula, 2
associated with adapted formula), 4 resumed enteral
nutrition with hydrolyzed milk, the remaining 4 did not
resume enteral nutrition because they died earlier. After
enteral nutrition reintroduction, it is necessary to assist
the newborn until full enteral feeding is reached: this
interval in our population lasted after 17.2 ± 8.2 days on
average.
Parenteral nutrition
Neonates with NEC should start early parenteral nutri-
tion with an adequate dose of amino acids (3.5–4 g/kg/
day), in order to maintain a positive nitrogen balance, an
improvement of weight growth and allowing the repair
of damaged tissues [1, 23–25]. Parenteral nutrition can
be discontinued when enteral nutrition is sufficient to
meet the nutritional needs. Prolonged parenteral nutri-
tion is associated with higher risk of infections and
metabolic problems, such as dyslipidemia and liver dis-
ease. The duration of parenteral nutrition in our series is
particularly long if compared to other studies in the lit-
erature, but this data could be due to the prematurity
and severity of NEC in our newborns. In our series, par-
enteral nutrition was started on average on the second
day of life and practiced for an interval of 50 ± 28 days.
In our case series, 12 newborns received olive oil lipid
emulsions; 5 received soybean lipid emulsions; finally, 1
newborn practiced parenteral nutrition without lipids.
Main metabolic complications of the parenteral nutri-
tion are liver disease and intestinal failure (IFALD) [26].
These complications incidence could be modified by re-
ducing the duration of parenteral nutrition, preferring
cyclic infusions and using suitable lipid mixtures. Several
factors should be taken into consideration when choos-
ing the lipid emulsion to use for parenteral: the content
of essential fatty acids, the ratio of omega-6 and omega-
3 and the amount of α-tocopherol and phytosterols.
Soy-bean lipid emulsions have an omega-6: omega-3
Table 4 Systemic signs of NEC
n %










Flecked skin 1 5.6
Hyponatremia 1 5.6
Metabolic acidosis 1 5.6
Table 5 Radiological sign of NEC
n %
Pneumoperitoneum 7 38.9
Air fluid levels 7 38.9
Intestinal distension 7 38.9
Failure to gasification straight 6 33.3
Portal pneumatosis 1 5.6
Aerobilia 1 5.6
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ratio of 7:1, while the ideal ratio should be 4: 1 [27, 28].
In addition, they have a high content of phytosterols
which cause liver inflammation and cholestasis [29, 30].
Fish oil lipid emulsions are mainly composed of omega-
3 and contain low amounts of omega-6 [31]. Therefore,
fish oil emulsions are approved as IFALD therapy, but
not for ordinary pediatric parenteral nutrition due to the
risk of deficiency of essential omega-6 fatty acids.
Recently, new lipid mixtures called Smoflipid have
been developed. They are composed by soybean oil
(30%), coconut oil (30%), olive oil (25%) and fish oil
(15%).
In children with cholestatic jaundice, there is an im-
provement in liver function after switching from soy-bean
lipid emulsions to Smoflipid [32]. Smoflipid has a positive
impact on liver enzymes thanks to the low content of
phytosterols and to the high content of vitamin E. Its use
determines a reduction in the lipid peroxidation and an
optimization of the ratio between PUFA omega-3: omega-
6 which creates a minor pro-inflammatory insult [33].
Surgical NEC treatment
In cases of NEC complicated by intestinal perforation,
surgery is required. In our sample, 14 newborns under-
went surgery. Among the 14 operated infants, 5 under-
went intestinal resection with enterostomy packaging, 5
had enterostomy packaging only, 2 underwent a laparot-
omy without resection or enterostomy, and finally 2
were treated exclusively with the placement of an ab-
dominal drainage. After extensive bowel resections intes-
tinal failure can develop [34]. This condition can be
overcome thanks to an intestinal adaptation that allows
the achievement of enteral autonomy [35]. The length of
the residual intestine and the type of nutrition influence
intestinal adaptation. Post-operative nutrition strategies
that aim to enhance intestinal adaptation are a corner-
stone of treatment.
Enteral nutrition in surgical NEC
In our series, patients who received surgery resumed en-
teral nutrition 17.7 ± 17.9 days after the intervention.
Figure 4 describe the distribution of different intervals of
enteral refeeding in patients who underwent surgery. 7
newborns were refed with breast milk (4 exclusively, 3
together with the hydrolyzed formula), while 4 took the
enteral exclusively with the hydrolyzed formula. Breast
milk offers numerous benefits on the intestinal adapta-
tion, thanks to the high content of growth factors [36].
Breast milk contains oligosaccharides such as 2-
fucosyllactose (2-FL) which positively regulate the intes-
tinal microbiome by stimulating the proliferation of
enterocytes [37].
Parenteral nutrition in surgical NEC
In patients of our series with NEC at stage III (n =
14), parenteral was practiced for 53.4 ± 29 days: 11/14
received olive oil lipid emulsions, 2/14 soybean lipid
emulsions, finally 1/14 received lipid-free emulsions.
Surgical NEC typically requires prolonged use of
parenteral nutrition (> 21 days) [5]. Patients with
fewer residual bowels require more days of parenteral
nutrition [38–42]. Parenteral support after 28 days of
surgery is associated with an increase in mortality at
1 year [43]. In clinical practice, intestinal failure can
be indirectly measured by the length of parenteral nu-
trition required for normal or recovery growth [44].
Use of supplements
Ostomies result in losses of mineral salts and micronu-
trients, especially zinc. Intestinal resections alter the
Fig. 4 Distribution of days between surgery and enteral re-feeding
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absorption of certain nutrients, depending on the
intestinal tract resected. In case of jejunostomy, the
absorption of iron and zinc can be impaired. In ileal
resections and fasting, the absorption of vitamin B12
and the resorption of biliary salts is altered. In addition,
infants who practice prolonged exclusive parenteral may
develop carnitine deficiency. Prolonged parenteral can
cause cholestasis that reduces the resorption of fat-
soluble vitamins.
Conclusions
Our report confirm that NEC may be considered a het-
erogeneous and nutritional disease, which poses a series
of problems, mainly related to different patients with dif-
ferent risk factors related to different ages, with very dif-
ferent surgical approaches. For this reason, each patient
has specific nutritional risks, and should be evaluated by
nutritionists or neonatologists with specific knowledge
to assess a proper management, a correct fasting period
and how to manage parenteral nutrition.
Breast milk represents the only real prevention of
NEC, and it is also beneficial for newborns after surgery.
It is ideal for re-nutrition both for digestibility and for
the ability to stimulate intestinal trophism [19, 20, 45].
No other nutritional strategies were found useful in the
prevention of NEC; even early enteral nutrition (< 96 h)
or intermittent feeding, which can be considered benefi-
cial and safe practices for low-birth weight infants and
preterms, do not reduce the incidence of NEC [45–47].
The main challenge in the management of this disease
is an early diagnosis, which could lead to a reduction in
terms of mortality and morbidity. The identification of a
specific biomarker could then allow early diagnosis or
provide information on prognosis and severity.
Regarding different nutritional strategies in newborns
with NEC, an excessively prolonged fasting should be
avoided because it could increase the duration of paren-
teral nutrition and promotes intestinal atrophy. Enteral
nutrition should be introduced within 7 days in stage I
and II cases of NEC, and within 14 days in patients on
stage III NEC [5].
Newborn with NEC have various risk factors for
nutritional deficiencies: prematurity, intestinal damage,
fasting, prolonged parenteral nutrition and possible pres-
ence of enterostomies [5]. A macronutrient deficiency
can cause energy protein malnutrition. Deficiencies in
micronutrients can interfere with the normal growth
process, therefore exogenous supplementation is often
required [8].
In cases of possible surgical therapy, it must be consid-
ered that it could cause malabsorption, ending up in a
possible short bowel syndrome. Considering all these
implications, in order to manage and limit the sequelae
of the disease, the newborn with NEC needs for a
periodic and frequent multidisciplinary evaluation made
by a neonatologist, surgeon and nutritionist.
Our study can be considered limited by the single cen-
ter approach, although this decreases the homogeneity
in the management approach of disease. Another limit
of this study, can be the variability in weight and gesta-
tional age of preterms.
Principal strength of this study, instead, is the number
of patients for such a rare disease, which helped to iden-
tify the epidemiological characteristics of NEC patients
and the different possible therapeutical management that
can be performed.
More studies are needed to identify the ideal nutri-
tional strategy for these infants and how to identify spe-
cific pathology markers. Furthermore, a prospective
evaluation of neonates with NEC may be useful to evalu-
ate the quality of life of these patients in the long-term,
considering the nutritional, auxological and neurological
outcomes.
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